|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TMEM14C |
Gene summary for TMEM14C |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TMEM14C | Gene ID | 51522 |
| Gene name | transmembrane protein 14C | |
| Gene Alias | C6orf53 | |
| Cytomap | 6p24.2 | |
| Gene Type | protein-coding | GO ID | GO:0002262 | UniProtAcc | A0A024R001 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51522 | TMEM14C | CA_HPV_1 | Human | Cervix | CC | 4.84e-17 | -3.80e-01 | 0.0264 |
| 51522 | TMEM14C | N_HPV_1 | Human | Cervix | N_HPV | 1.33e-02 | -5.78e-02 | 0.0079 |
| 51522 | TMEM14C | CCI_1 | Human | Cervix | CC | 3.39e-14 | -7.35e-01 | 0.528 |
| 51522 | TMEM14C | CCI_2 | Human | Cervix | CC | 5.67e-04 | -5.48e-01 | 0.5249 |
| 51522 | TMEM14C | CCI_3 | Human | Cervix | CC | 4.29e-14 | -6.88e-01 | 0.516 |
| 51522 | TMEM14C | CCII_1 | Human | Cervix | CC | 2.46e-22 | -7.23e-01 | 0.3249 |
| 51522 | TMEM14C | sample1 | Human | Cervix | CC | 1.50e-04 | -4.71e-01 | 0.0959 |
| 51522 | TMEM14C | H2 | Human | Cervix | HSIL_HPV | 7.39e-03 | -2.62e-01 | 0.0632 |
| 51522 | TMEM14C | L1 | Human | Cervix | CC | 1.64e-08 | -3.64e-01 | 0.0802 |
| 51522 | TMEM14C | T1 | Human | Cervix | CC | 6.62e-09 | -4.29e-01 | 0.0918 |
| 51522 | TMEM14C | HTA11_3410_2000001011 | Human | Colorectum | AD | 3.51e-07 | 2.17e-01 | 0.0155 |
| 51522 | TMEM14C | HTA11_2487_2000001011 | Human | Colorectum | SER | 2.81e-02 | 2.81e-01 | -0.1808 |
| 51522 | TMEM14C | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.57e-12 | 5.40e-01 | -0.0811 |
| 51522 | TMEM14C | HTA11_78_2000001011 | Human | Colorectum | AD | 4.56e-10 | 4.49e-01 | -0.1088 |
| 51522 | TMEM14C | HTA11_347_2000001011 | Human | Colorectum | AD | 1.23e-29 | 6.67e-01 | -0.1954 |
| 51522 | TMEM14C | HTA11_411_2000001011 | Human | Colorectum | SER | 8.68e-03 | 6.23e-01 | -0.2602 |
| 51522 | TMEM14C | HTA11_83_2000001011 | Human | Colorectum | SER | 1.29e-03 | 3.40e-01 | -0.1526 |
| 51522 | TMEM14C | HTA11_696_2000001011 | Human | Colorectum | AD | 4.44e-10 | 3.42e-01 | -0.1464 |
| 51522 | TMEM14C | HTA11_866_2000001011 | Human | Colorectum | AD | 1.82e-07 | 2.81e-01 | -0.1001 |
| 51522 | TMEM14C | HTA11_1391_2000001011 | Human | Colorectum | AD | 3.01e-07 | 3.37e-01 | -0.059 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003009910 | Cervix | CC | myeloid cell differentiation | 83/2311 | 381/18723 | 1.31e-07 | 6.42e-06 | 83 |
| GO:000226210 | Cervix | CC | myeloid cell homeostasis | 43/2311 | 157/18723 | 2.66e-07 | 1.12e-05 | 43 |
| GO:00068399 | Cervix | CC | mitochondrial transport | 60/2311 | 254/18723 | 4.21e-07 | 1.67e-05 | 60 |
| GO:003410110 | Cervix | CC | erythrocyte homeostasis | 37/2311 | 129/18723 | 5.16e-07 | 1.93e-05 | 37 |
| GO:003021810 | Cervix | CC | erythrocyte differentiation | 34/2311 | 120/18723 | 2.00e-06 | 6.18e-05 | 34 |
| GO:004887210 | Cervix | CC | homeostasis of number of cells | 61/2311 | 272/18723 | 2.17e-06 | 6.55e-05 | 61 |
| GO:003009915 | Cervix | HSIL_HPV | myeloid cell differentiation | 36/737 | 381/18723 | 1.19e-06 | 5.62e-05 | 36 |
| GO:000226215 | Cervix | HSIL_HPV | myeloid cell homeostasis | 18/737 | 157/18723 | 4.75e-05 | 1.21e-03 | 18 |
| GO:003410115 | Cervix | HSIL_HPV | erythrocyte homeostasis | 16/737 | 129/18723 | 4.76e-05 | 1.21e-03 | 16 |
| GO:003021815 | Cervix | HSIL_HPV | erythrocyte differentiation | 14/737 | 120/18723 | 2.67e-04 | 4.54e-03 | 14 |
| GO:000683914 | Cervix | HSIL_HPV | mitochondrial transport | 22/737 | 254/18723 | 4.72e-04 | 6.90e-03 | 22 |
| GO:004887215 | Cervix | HSIL_HPV | homeostasis of number of cells | 21/737 | 272/18723 | 2.64e-03 | 2.54e-02 | 21 |
| GO:003009925 | Cervix | N_HPV | myeloid cell differentiation | 33/534 | 381/18723 | 1.61e-08 | 2.52e-06 | 33 |
| GO:000683924 | Cervix | N_HPV | mitochondrial transport | 22/534 | 254/18723 | 4.05e-06 | 1.60e-04 | 22 |
| GO:003410125 | Cervix | N_HPV | erythrocyte homeostasis | 14/534 | 129/18723 | 1.92e-05 | 5.56e-04 | 14 |
| GO:004887225 | Cervix | N_HPV | homeostasis of number of cells | 21/534 | 272/18723 | 3.79e-05 | 9.37e-04 | 21 |
| GO:003021824 | Cervix | N_HPV | erythrocyte differentiation | 13/534 | 120/18723 | 3.86e-05 | 9.41e-04 | 13 |
| GO:000226225 | Cervix | N_HPV | myeloid cell homeostasis | 15/534 | 157/18723 | 4.46e-05 | 1.04e-03 | 15 |
| GO:0006839 | Colorectum | AD | mitochondrial transport | 102/3918 | 254/18723 | 1.87e-12 | 3.08e-10 | 102 |
| GO:0034101 | Colorectum | AD | erythrocyte homeostasis | 51/3918 | 129/18723 | 1.07e-06 | 3.59e-05 | 51 |
| Page: 1 2 3 4 5 6 7 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TMEM14C | SNV | Missense_Mutation | rs200488333 | c.266C>T | p.Ala89Val | p.A89V | Q9P0S9 | protein_coding | tolerated(0.15) | benign(0.162) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| TMEM14C | SNV | Missense_Mutation | c.148N>A | p.Leu50Met | p.L50M | Q9P0S9 | protein_coding | deleterious(0.03) | probably_damaging(0.961) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| TMEM14C | SNV | Missense_Mutation | novel | c.322N>C | p.Phe108Leu | p.F108L | Q9P0S9 | protein_coding | tolerated(1) | benign(0) | TCGA-DM-A28C-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| TMEM14C | SNV | Missense_Mutation | novel | c.131N>C | p.Phe44Ser | p.F44S | Q9P0S9 | protein_coding | deleterious(0.02) | probably_damaging(0.965) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| TMEM14C | SNV | Missense_Mutation | rs750952687 | c.301N>A | p.Ala101Thr | p.A101T | Q9P0S9 | protein_coding | tolerated(0.42) | benign(0.028) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TMEM14C | SNV | Missense_Mutation | novel | c.70N>A | p.Gly24Ser | p.G24S | Q9P0S9 | protein_coding | deleterious(0) | probably_damaging(0.938) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TMEM14C | SNV | Missense_Mutation | novel | c.83N>A | p.Gly28Asp | p.G28D | Q9P0S9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TMEM14C | SNV | Missense_Mutation | c.226N>G | p.Met76Val | p.M76V | Q9P0S9 | protein_coding | deleterious(0) | possibly_damaging(0.457) | TCGA-K7-A5RG-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| TMEM14C | SNV | Missense_Mutation | c.134G>T | p.Gly45Val | p.G45V | Q9P0S9 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-RC-A7SK-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
| TMEM14C | SNV | Missense_Mutation | c.236G>C | p.Arg79Thr | p.R79T | Q9P0S9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-44-8117-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |